medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2005, Number 1

<< Back Next >>

Ann Hepatol 2005; 4 (1)

Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data

Méndez-Sánchez N, Villa AR, Chávez-Tapia NC, Ponciano-Rodriguez G, Almeda-Valdés P, González D, Uribe M

Language: English
References: 35
Page: 52-55
PDF size: 50.76 Kb.


Text Extraction

Background and Aims. The epidemiology of liver cirrhosis differs across sex, ethnic groups, and geographic regions. In 2000, chronic liver disease was the fifth leading cause of death in Mexico. Accurate knowledge of the demographics of liver disease is essential in formulating health-care policies. Our main aim was to project the trends in liver disease prevalence in Mexico from 2005 to 2050 based on mortality data. Methods. Data on national mortality reported for the year 2002 in Mexico were analyzed. Specific-cause mortality rates were calculated for a selected age population (≥ 25 years old) and classified by sex and projected year (2005–2050). The following codes of the International Classification of Diseases for liver diseases were included: non-alcoholic chronic liver disease and cirrhosis, alcoholic liver disease, liver cancer, and acute and chronic hepatitis B and C infection. The projected prevalence of a chronic liver disease was estimated using the following equation: P = (ID × T) / [(ID × T) + 1], where P = prevalence, ID = incidence density (mortality rate multiplied by 2), T = median survival with the disease (= 20 years). Results: Nearly two million cases of chronic liver disease are expected. Alcohol-related liver diseases remain the most important causes of chronic liver disease, accounting for 996,255 cases in 2050. An emergent syndrome is non-alcoholic liver disease, which will be more important that infectious liver diseases (823,366 vs 46,992 expected cases, respectively). Hepatocellular carcinoma will be the third leading cause of liver disease. Conclusions: Chronic liver disease will be an important cause of morbidity and mortality in the future. Preventive strategies are necessary, particularly those related to obesity and alcohol consumption, to avoid catastrophic consequences.


REFERENCES

  1. Mendez-Sanchez N, Uribe M. Conceptos actuales en Hepatología. 1st ed. 2003, Mexico: Masson-Doyma.

  2. Keeffe EB. Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology 2001; 120: 749-762.

  3. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology 2000; 31: 1014-1018.

  4. Secretaría de Salud M, Base de datos de información sobre mortalidad in http://www.salud.gob.mx/apps/htdocs/estadisticas/publicaciones/Mortalidad2000.zip. Access: 3th january 2005.

  5. Kleinbaum D, Kupper LL, Morgenstern H. Epidemiologic Research. Principles and Quantitative Methods. Van Nostrand Reinhold Company, New York, 1982: 120-121.

  6. Mendez-Sanchez N, Aguilar-Ramirez JR, Reyes A, Dehesa M, Juorez A, Castneda B, Sanchez-Avila F, Poo JL, Guevara Gonzalez L, Lizardi J, Valdovinos MA, Uribe M, Contreras AM, Tirado P, Aguirre J, Rivera-Benitez C, Santiago-Santiago R, Bosques-Padilla F, Munoz L, Guerroro A, Ramos M, Rodriguez-Hernandez H, Jacobo-Karam J. Etiology of liver cirrhosis in Mexico. Ann Hepatol 2004; 3: 30-33.

  7. Trevino-Zapata N. [Liver cirrhosis. Therapeutic, clinico-functional, anatomo-histopathological concept. Personal previous and current conditions]. Gac Med Mex 1969; 99: 162-173.

  8. Bustamante ME. [Alcoholism and its sociomedical consequences. Socioeconomic aspect]. Gac Med Mex 1974; 107: 227-253.

  9. Aceves Sainos D, Alcocer Murguia F, Hernandez Mateos R, Ibarra S, Marin P, Quijano Z, Valladares Sosa O, Garcia Romero H. [Epidemiology of hepatic cirrhosis]. Rev Gastroenterol Mex 1975; 40: 26-32.

  10. Dajer F, Guevara L, Arosamena L, Suarez GI, Kershenobich D. [Epidemiological aspects of alcoholic liver cirrhosis in Mexico]. Rev Invest Clin 1978; 30: 13-28.

  11. Kim WR, Brown RS, Jr., Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36: 227-242.

  12. Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. Semin Liver Dis 2004; 24: 217-232.

  13. Narro-Robles J, Gutierrez-Avila JH. [Ecological correlation between consumption of alcoholic beverages and liver cirrhosis mortality in Mexico]. Salud Publica Mex 1997; 39: 217-220.

  14. Lopez-Jimenez JL. [Alcohol consumption patterns in patients admitted to emergency services]. Salud Publica Mex 1998; 40: 487-493.

  15. Gordon H. Detection of alcoholic liver disease. World J Gastroenterol 2001; 7: 297-302.

  16. Fabregoule M, Eisenbeth R. [The role of nutritional factors in the etiology of hepatitis and cirrhosis]. Alger Medicale 1950; 54: 119-123.

  17. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123.

  18. Mendez-Sanchez N, Sanchez-Castillo CP, Villa AR, Madrigal H, Merino B, Garcia E, Lopez P, Pichardo-Ontiveros E, Uribe M. The relationship of overweight and obesity to high mortality rates from liver cirrhosis in Mexico. Ann Hepatol 2004; 3: 66-71.

  19. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004; 291: 2847-2850.

  20. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.

  21. Mendez-Sanchez N, Sanchez-Lara K, Villa AR, Bahena-Aponte J, Chavez-Tapia NC, Ramos MH, Uribe M. Adiponectin concentration as protective factor in hepatic steatosis. World J Gastroenterol 2005; in press.

  22. Tolman KG, Fonseca V, Tan MH, Dalpiaz A. Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med 2004; 141: 946-956.

  23. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395.

  24. Power C, Manor O, Matthews S. Child to adult socioeconomic conditions and obesity in a national cohort. Int J Obes Relat Metab Disord 2003; 27: 1081-1086.

  25. Melgar-Quinonez HR, Kaiser LL. Relationship of child-feeding practices to overweight in low-income Mexican-American preschool-aged children. J Am Diet Assoc 2004; 104: 1110-1119.

  26. Sherry B, Mei Z, Scanlon KS, Mokdad AH, Grummer-Strawn LM. Trends in state-specific prevalence of overweight and underweight in 2- through 4-year-old children from low-income families from 1989 through 2000. Arch Pediatr Adolesc Med 2004; 158: 1116-1124.

  27. Batey LS, Goff DC, Jr., Tortolero SR, Nichaman MZ, Chan W, Chan FA, Grunbaum J, Hanis CL, Labarthe DR. Summary measures of the insulin resistance syndrome are adverse among Mexican-American versus non-Hispanic white children: the Corpus Christi Child Heart Study. Circulation 1997; 96: 4319-4325.

  28. Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol 2004; 35: 1070-1082.

  29. Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, Bringman D, Martin LM, Assmann J, Gramlich T, Mullen KD, O’Shea R, Carey WD, Ferguson R. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004; 38: 705-709.

  30. Safdar K, Schiff ER. Alcohol and hepatitis C. Semin Liver Dis 2004; 24: 305-315.

  31. Jee SH, Ohrr H, Sull JW, Samet JM. Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. J Natl Cancer Inst 2004; 96: 1851-1856.

  32. Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 1985; 254: 3187-3189.

  33. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-338.

  34. Gonzalez L, Blanc JF, Cunha AS, Rullier A, Saric J, Bail BL, Balabaud C, Bioulac-Sage P. Obesity as a risk factor for hepatocellular carcinoma in a noncirrhotic patient. Semin Liver Dis 2004; 24: 415-419.

  35. Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C, Degos F, Farges O, Belghiti J. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004; 10: S69-S73.




2020     |     www.medigraphic.com